• Embed Doc
  • Copy Link
  • Readcast
  • Collections
  • CommentGo Back
Download
 
ATTACHMENT F
U.S. Patent No. 6,054,297
 
United States Patent [19]
Carter et al.
I llHlll1llllllllll
ll11111llllll11ll11
llll
111111111llI111ll1
USOC)6054297A
[II] Patent Number:6,054,297
1451
Date of Patent:Apr. 252000
1541[7S][?3]
1211
WI[@I
HUMANIZED ANTIBODIES AND METHODSFOR MAKING THEM
Inventors:
Paul J. Carter; Leonard G. Prvsta,
both of San Francisco, Calif.Assignee:
Genentech, Inc.,
South San Francisco,Calif.Appl. No.: 081437,642Filed:
May 9,199sRelated U.S. Application Data
Continuation of
application No. O7/934,373,Aug. 21, 1992,
Pat.No. 5,521,337,which is a continuation-in-partof appli- cation No. PCP/US92’05126, Jun. 15, 1992, which is acontinuation-in-part of applicaliou No. 07fll5,272, Jun. 14,1991, abandoned.
Int. CL7 ,.................... 61K 39/395; C12N
15/13;CO7K 16!00; CO7K 16/30U.S. Cl. . ._......_.......t.....35169.6; 435i69.7; 4351328;4351344; 5301387.3; 530:387.7; 530/3X8.8;53Oi389.7; 4241130.1; 424j133.1; 4241155.1;424i174.1; 424/13&l
Fieldof Search .5301387.3,387.7,
53OL388.8, 389.7; 424/130.1, 133.1, 138.1,
1.551,
174.1; 435/328,
344, 69.6,
69.74$X16,567
4.845.198
5,132;4055225,539
5,53(J)Ol5,558,%45,585,089$677.171S&93,761
References Cited
U.S. PATENT DGCIJMENTS311989 &billy et al.7i1989 Urdal et al. .7/1992 Hutton et al.
7/1993 Winter .6llYYh Queen et al.Y/1996 Bendig et al. .1211996 Quietal. . . .lo,‘1997 Hnddak et al. .1211997 Queen et al. .5,693,762 1211997 Queen et al. .$714,350 211998 Co et al. .5.775997Gil998 Hudziak et al.5,821,337 10!1998 Carter et al.5,859,205l/1999 Addnir et al. .
FOREIGN PATENT DOCUMENTS
8SO58/913!1992 AustralialXJ694 lO/lY84 European Pat. Off.175023 Al 1111984 European Pat. Off.0239400 A29!1987 European Pat Off. .239400323806Al328404Al338745Al365209.429!19877/19898119891011989411990
Ewopem at. ff.
EuropeanPat. off.EurooeanPat. off.
Euro&m Pat. Off. .European Pat. Off.65997A2 s/1990368684 5;1990Euo+an Pat. Off.403156 Al 1211990
EuropeanPat Off.
4383101~ 711991
EuropeanPat. off.
438312A2 7!‘1991European Pat Off. .440351A2 8!1991 Euro+m Pal. Off. .0 460 167 Bt11/1991
EuropeanPat. Off.0 519 596 Al12il992 EuropeanPat. Off.0 592 106 Al4/1994 EuropeanPat. Off.620276lo!1994 EuropeanPat. Off. .
E?ur&an Pat. Off. .124;133.1682040 Alll/lYYS European Pat. Off.451216 Bll/1996
European Pat. Off.
432249 BlY/1996
European Pat. 011.
2 158941IO/1987 United KingdomWO 87!026?1511987 WIPO .WO88lOY3441211988
WPO.
wo 89101783311989 wIPowo 89!09622611989 WIPOWO 59:06692?/19S9 WIPO.WO9m78617jl990 WIPOWO Vl/U7492S/1991 \v1wwo 91:0?500511991 WIPOWO9l.f09966711991 WIPOwo 9UO9967711991 WIPOWO91/09968 7/19Yl WIPOwo Yzo104:l/1992 WIPOWO92:04380311992 wIPoWO 92/04381 31lYY2 WIPOWO 92105274411992 WIPOwo Y2i113837/1992 WIPO .
WO Y2/11018 Y;I9Y2 WIPO .WO 9U15683 911992 WIPO
WO92/16562 1011992
WIPO.WO 92f22653 12/1992 WIPO .
WO 93102191 211993 WTPO94/11509 SllYY4 WIPOWO 94:12214 611994 WIT’0
OTHER PUBLICATIONSGarrido, M.A. Devel. Biol. Stand (Switzerland) 71: 33-42,1YYO.Queen et al., PNAS, USA, 86:10029-10033, 1989.Foote, J. et al., Nova Acta Leopoldina NF 61 No.269:103-110, 1989Riechman, I.. et al., Nature. 332(24).3X3-327, 1988.Kabat, E.A. et al., Sequences of proteins of ImmunologicalInterest, NIH, Bethesda, MD, pp. iii-xxvii, 41-175, 1987.Margni, R.A. et al., Ann Rev. Immunol. 6:53S-54, 1988.Fendly, B.R4. et al., Cancer lies. 50: 1550-1558, 1990.KuiJpers K.C. et al., J. Immunol. 144(9): 3281-7, 1990Brown, Jr. et al., “Anti-Tat-H, a humaniz&d antibody to theinterleukin 2 rece.ptor, prolongs primate cardiac’allograftsurvival” Proc. Natl. Acud. Sci. Us4 882663-2667 (1991).Casale et al., “Use of an anti-IgE humanized monoclonalantibody in ragweed-induced allergic rhinitis” J. $/lerg)Clirl. Immunol. lOO:llO-121 (1997).Fahy et al., “The Effect of an Anti-IgE Monoclonal Anti-body ou the Early-and Late-Phase Respomses to AllergenInhalation in Asthmatic Subjects” Am J. Respir. Cd. CareMed 155:1828-1834 (1997).Mathieson et al., “Monoclonal-Antibody Therapy in Sys-temic Vasculitis” !Vew En&wzd J. of Medicine pp. X&254Jul. 1990).(List continued on next page.)Primary Examin~r~au1.a K. HutzellAssistant Examiner-Julie E ReeyesAffornq, Agent, or Firm-Wendy M. Lee[571
ABSTRACT
Variant immunoglobulins. particularlv humanized antibodypolypeptides are provided, along v&h methods for theirpreparation and USC.Consensus immunoglobulin sequcnccsand structural models are also provided.
30 Claims, 12 Drawing Sheets
 
6,054,297
Page 2OTHER PUBLICATIONSOsborne, Randall, “Full Approval of Breast Cancer DrugExpected by Year’s End, FDA Panel OKs Genmtech’sHerceptin” Daily Ink pp. 1-2 (Sep. 4,1998).Presta et al., “Humanization of an anti-vascular endothelialgrowth factor monoclonal antibody for the therapy of solidtumors and other disorders” Cancer
Research 57
(20):459.3-4599 (Oct. 15, 1997).“Biosym Technologies” in new Products, Chemical DesignAutomation 3 (Dec. 1988).“Polygen Corporation” in new Products, Chemical DesignAutomation 3 Nov. 1988).Adair et al., “Humanization of the murine anti-human CD3monoclonal antibody OKT3”
Hum.
Arrribad.
Hybridomns
5:41-47 (1994).Chothia et al., “Principles of protein-protein recognition”
Nature 256:705-708
(1975).Chothia et al., “Transmission of conformational change ininsulin” ,I;nture 302:SOO-505 1983).
Corti
et al., “Idiotope Determining Regions of a MouseMonoclonal Antibody and Its Humanized Versions” J. Mel
Biol. 235353-60
(1994).Couto et al..,“Anti-BA46 Monoclonal Antibody Mc3Humanization Using a Novel Positional Consensus and inVivo and in Vitro Characterization”
Cancer ResearchSupplement
55:1717-1722 (1995).Couto et al,“Humanization of KC4G3, an Anti-HumanCarcinoma Antibody”
Hybridoma
13:215-219 (1994).Ellis et al., “EngineeredAnti-CD38 Monoclonal Antibodiesfor Immunotherapy of Multiple Myeloma” Z’Zze
ournal of
hFflUnOiOgY PIP.
925-937 (1995).Hieter et al., “Evolution of Human lmmunoglobulin K JRegion Genes” The
Journal
of
Riological Chemistry
25?:1516-1522 (1982).Lesk, Arthur M., “How Different Amino Acid SequencesDetermine Similar Protein Structures: The Structure andEvolutionary Dynamics of the Globins” J. Mol. BioZ.13622.5-270 (1980).Matsumura et al., “Hydrophobic stabilization in T4lysozyme determined directly by multiple substitutions ofBe 3”
Naiure 334:4Of&410
(1988).Morrison, S. L., “Transfectomas Provide Novel ChimericAntibodies” Science 229:1202-1207 (Sep. 20, 1985).Nakatani et al., “Humanization of mouse anti-human IL-2receptor antibody B-B10”
Protein Engineering 7:4X-443
(1994).Ohtomo et al., “Humanization of Mouse ON.%M21 Anti-body with the Aid of Hybrid Variable Regions”
hlolecularZmmunoiogy 32407-637 (1977).
Padlan et al., “Model-Building Studies of Antigen-BindingSites: The Hapten-Binding Site of MOPC-315” C.S.
Hur-bor Symp. &ant. Biol. 41:627-637
(1977).Rodrigues et al., “Engineering a humanized bispecificF(ab’), fragment for improved binding to T cells” Iti. .Z.Cancer (Suppl.) 7:45-50 (1992).Sha et al., “A heavy Chain Grafted Antibody that Recog-nizes the Tumor-Associated TAG72 Antigen” Cancer
Dio-therapy
9341-349 (1994).Tempest et al.,“Identification of framework residuesrequired to restore antigen binding during reshaping of amonoclonal antibody against the glycoprotein gB of humancytomegalovirus” Z/,rl.
. Biol. Macrcmol. 17:37-U (1995).
Tramontano, “Structural Determinants of the Conformalionsof Medium-Sized Loops in Proteins”
Proteins 6:382-394
(1989).Uchiyama et al., “A Monoclonal Antibody (ANTI-Tat)Reactive with Activated and Punctionally Mature Human ‘ICells”
Journal of Immunology
126:3393-1397 (1981).Vincenti et al., “lnterleukin-2-Receptor Blockade withDaclizumab to Prevent Acute Rejection in Renal Transplan-tation” New Z?ngl.J.
Med.
338:161-165 (1998).Vitetta et al., “Redesigning Nature’s Poisons to CreateAnti-Tumor Reagents” Science 238:1098-1104 (1987).Waldmann et al., “Interleukin 2 Receptor (Wc Antigen)Expression n HTLV-l-associated Add1 T-Cell Leukemia”Cancer Research 45:455Y&562s (1985).Waldmann, Thomas A., “The Structure, Function, andExpression of Interleukin-2 Receptors on Normal andMalignant Lymphocytes” Sn’eFlce232:?27-732 (1986).Wu et al., “An Analysis of the ,Sequences f the VariableRegions of Bence Jones Proteins and Myeloma Light Chainsand Their Implications for Antibody Complementadty”
Journal of ExperimentalMedicine
132:211-250 (1970).Amit et al., “Three-Dimensional Structure of an Anti-gen-Antibody Complex at 2.8 A Resolution”
Science
233:747-753 (Aug. 1986).Amzel et al., “The Three Dimensional Structure of a Com-bining Kegion-Ligand Complex of Immunglobulin NEW at3.5-A Resolution”
Proc. Natl. Acad. Sri. USA
X(4):1427-1430 (Apr. 1974).Baselga et al.,“Phase II Study of Weekly IntravenousRecombinant Humanized Anti-p185HER2 MonoclonalAntibody in Patients with HER2/neu-Overexpressing Meta-static Breast Cancer”
J. Clin. Oncoi. 14(3):737-744
(1996).Beverley & Callard, “Distinctive functional charcteristics ofhuman “‘I” lymphocytes detlned by E resetting or a mono-clonal anti-T cell antibody”
European Journal of Imnumol-
ogy 11:329-334 (1981).Bird et al., “Single-chain antigen-bmding proteins” Scit?nce242:423-426 (Oct. lY88).Brennan et al., “Preparation of bispecific antibodies bychemical recombination of monoclonal immunoglobulin Glfragments”
Science 22981-83
(Jul. 1985).Bruccoleri et al., “Structure of antibody hypervariable loopsreproduced by a conformational search algorithm”
Nature
335:564-S6S (Oct. 1988).Caron et al., “Biological and Immunological Features ofHumanized Ml95 (Anti-CD33) Monoclonal Antibodies”
Cancer Research 52:6761-6767 (Dec.
1992).Chothia & Lesk, “The relation between the divergence ofsequence and structure in proteins”
EMBO Journal
5(4):823-826 (lY86).Co &. Queen, “Humanized antibodies for therapy” NNfure351:501-502 (Jun. 1991).Co et al., “Chimeric and Humanized Antibodies with Speci-ficity for the CD33 Antigen”
J. of
Z771~71unol0~gy
148(4):1149-1154 (Peb. 1992).Co et al., “Humanized Anti-Lewis Y Antibodies: In VitroProperties and Pharmacokinetics in Rhesus Monkeys” Can-cer
Research
56:1118-1125 (Mar. 1996).Colman et al., “Crystal and Molecular Structure of theDimer of Variable Domains of the Bence-Jones ProteinROY”
J. Mol. Riol.
116:7-3-79 (1977).Colman et al., “Three+limensional structure of a complex ofantibody with influenza virus neuraminidase”
Nature
326:358-363 (Mar. 1987).
of 00

Leave a Comment

You must be to leave a comment.
Submit
Characters: ...
You must be to leave a comment.
Submit
Characters: ...